- Home
- EDIT vs GF Comparison
EDIT vs GF Comparison
Compare EDIT & GF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- GF
- Stock Information
- Founded
- EDIT 2013
- GF 1990
- Country
- EDIT United States
- GF Germany
- Employees
- EDIT N/A
- GF N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- GF Investment Managers
- Sector
- EDIT Health Care
- GF Finance
- Exchange
- EDIT Nasdaq
- GF Nasdaq
- Market Cap
- EDIT 108.1M
- GF 167.2M
- IPO Year
- EDIT 2016
- GF N/A
- Fundamental
- Price
- EDIT $1.25
- GF $10.07
- Analyst Decision
- EDIT Buy
- GF
- Analyst Count
- EDIT 14
- GF 0
- Target Price
- EDIT $8.08
- GF N/A
- AVG Volume (30 Days)
- EDIT 2.5M
- GF 28.1K
- Earning Date
- EDIT 03-05-2025
- GF 01-01-0001
- Dividend Yield
- EDIT N/A
- GF 0.82%
- EPS Growth
- EDIT N/A
- GF N/A
- EPS
- EDIT N/A
- GF N/A
- Revenue
- EDIT $32,314,000.00
- GF N/A
- Revenue This Year
- EDIT N/A
- GF N/A
- Revenue Next Year
- EDIT N/A
- GF N/A
- P/E Ratio
- EDIT N/A
- GF N/A
- Revenue Growth
- EDIT N/A
- GF N/A
- 52 Week Low
- EDIT $1.12
- GF $7.38
- 52 Week High
- EDIT $7.41
- GF $9.41
- Technical
- Relative Strength Index (RSI)
- EDIT 41.70
- GF 57.31
- Support Level
- EDIT $1.24
- GF $10.14
- Resistance Level
- EDIT $1.32
- GF $10.28
- Average True Range (ATR)
- EDIT 0.11
- GF 0.14
- MACD
- EDIT -0.03
- GF -0.07
- Stochastic Oscillator
- EDIT 2.94
- GF 32.56
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.